Loading
A phase 2 trial of Relacorilant and Bevacizumab in ovarian cancer and endometrial cancer, run by Corcept Therapeutics, now recruiting.
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers is a phase 2 interventional study registered as NCT06906341 by Corcept Therapeutics, with 270 participants planned, started 2025-04-11 and due to reach its primary completion in 2026-08. Interventions recorded: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2 and Bevacizumab 10 mg/kg.
Shares Corcept Therapeutics, Relacorilant, Cytotoxic chemotherapy and the tag pipeline.
Shares Corcept Therapeutics and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cytotoxic chemotherapy and the tag pipeline.